Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;36(10):2451-2452.
doi: 10.1002/mds.28754.

Reply to: "Application of the mPSPRS to the Salerno Cohort"

Gesine Respondek  1 , Günter U Höglinger  1   2
Affiliations
Comment

Reply to: "Application of the mPSPRS to the Salerno Cohort"

Gesine Respondek et al. Mov Disord. 2021 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • A Modified Progressive Supranuclear Palsy Rating Scale.
    Grötsch MT, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, Huber MK, Klietz M, Krey LFM, Levin J, Jecmenica-Lukic M, Macías-García D, Meissner WG, Mir P, Morris H, Nilsson C, Rowe JB, Seppi K, Stamelou M, van Swieten JC, Wenning G, Del Ser T, Golbe LI, Höglinger GU; Describe PSP Study Group, the ProPSP Study Group, and the Movement Disorder Society-Endorsed PSP Study Group. Grötsch MT, et al. Mov Disord. 2021 May;36(5):1203-1215. doi: 10.1002/mds.28470. Epub 2021 Jan 29. Mov Disord. 2021. PMID: 33513292
  • Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP-RS and vPSP.
    Abate F, Tepedino MF, Barone P, Picillo M. Abate F, et al. Mov Disord. 2021 Oct;36(10):2449-2451. doi: 10.1002/mds.28757. Mov Disord. 2021. PMID: 34658064 No abstract available.

References

    1. Grötsch MT, Respondek G, Colosimo C, et al. A modified progressive Supranuclear palsy rating scale. Mov Disord 2021;36(5):1203-1215. https://doi.org/10.1002/mds.28470.
    1. Abate F, Tepedino MF, Barone P, Picillo M. Application of the mPSPRS to the Salerno cohort and a comparison between PSP-RS and vPSP. Mov Disord. in press.
    1. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130(6):1552-1565.
    1. Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014;29(4):470-478.
    1. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014;13(7):676-685.

LinkOut - more resources